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Abstract
Treatment of non-small-cell lung cancer is dependent on disease stage. For patients with
metastasis or locally advanced disease, the importance of finding therapeutic schemes that may
benefit this population is important. This review discusses therapeutic options for first- and
second-line treatment in patients with advanced non-small-cell lung cancer. According to current
data, the combination of two cytotoxic agents is the optimum first-line treatment for patients
with non-small-cell lung cancer and performance status of 0–1. Addition of bevacizumab has
shown to provide an even longer survival and to increase response rate. Within the first-line
setting, erlotinib appears to be effective in the treatment of elderly patients who would not
derive a benefit from standard chemotherapy or those refusing standard chemotherapy. The
administration of erlotinib as first-line maintenance therapy is being assessed. There are
currently three drugs approved for second-line treatment of patients with advanced non-small-
cell lung cancer after failure of first-line chemotherapy. These drugs have proven to be effective
in phase III trials. In the phase III trial BR.21 study, the response rate was 8.9% in the erlonitib
group, and less than 1% in placebo; median response duration was 7.9 months and 3.7 months,
respectively; and the median survival was 6.7 months and 4.7 with erlotinib and placebo,
respectively. One-year survival was 31% and 21% with erlotinib and placebo, respectively. In
addition, the BR.21 trial revealed that significantly greater improvements in overall quality of life
and in both physical and emotional functioning were observed in the erlotinib arm as compared
with the placebo arm. Erlotinib is not significantly associated with hematologic adverse effects.
Erlotinib is administered orally, and does not require concomitant administration of other drugs,
thus causing patients less inconvenience. Analysis of data from different subgroups included in
the BR.21 trial show that overall survival is similar among women and men, among patients with
adenocarcinoma and epidermoid carcinoma or Asian patients compared with other ethnicities.
Combination of erlotinib and bevacizumab in the second-line treatment of patients with
advanced disease has been evaluated as anti-angiogenic properties. This combination therapy has
provided promising results which should be confirmed in future studies.
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Background
Non-small-cell lung cancer (NSCLC) accounts for approx-
imately 85% of all cases of lung cancer, the most common
cause of death from cancer in men and second only to
breast cancer in women[1,2]. Treatment is dependent on
disease stage [1]. Surgery is the treatment of choice for
early-stage localized disease. Multimodal therapy remains
the norm for patients with locally advanced disease, and
patients with advanced metastatic disease derive a benefit
from palliative chemotherapy. About 40% of patients
with NSCLC present at an advanced stage, with metastasis
or locally advanced disease, which underscores the impor-
tance of finding therapeutic schemes that may benefit this
large patient population. When selecting the treatment for
these patients it is of utmost importance to take into
account their performance status (PS), which should be
considered an important determinant of outcome [3].
Therapeutic options for first- and second-line treatment in
patients with advanced or metastatic NSCLC are discussed
below.
First-line treatment
Combination chemotherapy, usually platinum-based, is
currently the first-line therapy of choice [1,4]. Based on
various studies, doublet regimens combining cisplatin or
carboplatin with paclitaxel, gemcitabine, docetaxel, vinor-
elbine or irinotecan are administered. The choice of the
combination components varies in different countries.
For instance, in Europe cisplatin or carboplatin are
administered in comparable proportions in combination
with gemcitabine; while in the U.S. a combination of a
platinum compound and paclitaxel or docetaxel is more
common. Vinorelbine is indicated less often, and irinote-
can is mainly used in Japan.
Various studies have shown similar degrees of efficacy
among different combinations in the treatment of
advanced NSCLC. For instance, in a randomized trial
including over 200 patients in each study group, Kelly et
al compared paclitaxel plus carboplatin with vinorelbine
plus cisplatin and found similar efficacy with both combi-
nations [5]. Another study compared 4 different combina-
tions with cisplatin or carboplatin plus paclitaxel
(administered with cisplatin as reference combination),
docetaxel or gemcitabine in 1207 patients, and none of
the four combinations was found to offer a significant
advantage over the others in this indication [6]. In Japan,
cisplatin plus irinotecan was compared with cisplatin or
carboplatin plus paclitaxel, gemcitabine or vinorelbine,
and no significant differences were found either among
the different therapeutic regimens [7].
First-line treatment for elderly patients
In various regions of the world, including the United
Kingdom and Mexico, elderly patients (i.e., 70 years of age
or older) suffering from advanced NSCLC constitute a
special therapeutic challenge [8]. This population shows
lower tolerance to adverse effects associated with plati-
num therapeutic regimens, which in many cases may be
contraindicated due to impaired organ function and
comorbid conditions [9,10].The ELVIS trial, a rand-
omized double-blind study, evaluated the effect of vinor-
elbine on quality of life and survival of patients aged 70 or
older, as compared to best supportive care [11]. According
to data from the 161 patients included in the analysis,
vinorelbine showed superiority over best supportive care,
with a 1-year survival rate of 32% vs. 14% and a potential
improvement in quality of life. Later, also in Italy, the
MILES study, a multicenter trial, compared single-agent
chemotherapy with vinorelbine or gemcitabine versus
polychemotherapy with vinorelbine plus gemcitabine.
This trial analyzed data from 698 patients aged 70 years or
older (median age, 74; patients > 75 years of age, 39%),
and found no differences in survival (1-year overall sur-
vival rate, 28%–38%) among the 3 therapeutic regimens,
although the combination was found to be more toxic
than single agents [12]. Based on results from these and
other studies, an expert panel agreed that single-agent
chemotherapy with vinorelbine, gemcitabine or a taxane
is the optimal treatment for this population [8]. In addi-
tion, there is evidence that combinations including cer-
tain compounds may be of benefit and well tolerated in
elderly patients and few comorbid conditions [12,13].
However, since these are not the most common health
conditions in elderly patients, the most frequent indica-
tion is to administer the above mentioned single-agent
therapies [13].
Another first-line single-agent therapeutic option of bene-
fit to elderly patients with advanced NSCLC is erlotinib
administration. Results from a phase II multicenter open-
label trial including 80 patients aged 70 years or older
with NSCLC and no previous chemotherapy were recently
published [14]. Median survival was 11 months, and 1-
year survival was 46%, although an objective response
was found in 10% of patients. However, 41% of patients
remained with stable disease for at least 2 months.
As regards erlotinib, when considering the use of this type
of therapy, emphasis should not be placed on objective
response rate (since it is usually low) but on survival. It
should be noted that in this open-label study median sur-
vival and 1-year survival rates are similar, and even higher,
than those reported with chemotherapy [8].
Other data related to erlotinib administration as first-line
therapy for advanced NSCLC include those presented byBMC Proceedings 2008, 2(Suppl 2):S3 http://www.biomedcentral.com/1753-6561/2/S2/S3
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Sandler et al. [15] in a study of 127 patients with bronchi-
oloalveolar carcinoma, with a 29% objective response
rate. In another phase II trial including 53 unselected
patients, objective response rate was 23% (similar to that
obtained with chemotherapy), median survival was 60
weeks, and median time to disease progression was 84
days [16]. A randomized trial is required to confirm
results of this study. Finally, a phase II trial included 72
chemotherapy-naïve patients (median age 74.4 years)
with advanced NSCLC and PS 2 [17]. In these patients,
who have a worse prognosis than those with PS 0–1,
objective response rate was 8%, median survival was 5
months, and 1-year survival was 22%.
Erlotinib as first-line maintenance therapy
Another study assessing erlotinib in the first-line treat-
ment of NSCLC is the Sequential Tarceva in Unresectable
Non-Small-Cell Lung Cancer (SATURN) trial, recently
closed to enrolment of patients. This phase II trial evalu-
ates the efficacy of erlotinib as maintenance therapy for
patients with advanced NSCLC and no disease progres-
sion following four cycles of chemotherapy. After initial
chemotherapy, patients are randomly assigned to erlo-
tinib or placebo; the primary endpoint is progression-free
survival. Preliminary results are expected to be reported by
the end of 2008 [1].
Other therapeutic options
Another promising drug for first-line treatment of
advanced NSCLC is bevacizumab, a monoclonal antibody
directed against the vascular endothelial growth factor,
which when administered concomitantly with chemo-
therapy (carboplatin plus paclitaxel), and as maintenance
single-agent therapy following six cycles of combination
chemotherapy, increased overall survival from 10.3
months to 12.3 months and response rate from 15% to
35% [1]. Progression free survival was increased after ini-
tial chemotherapy with cisplatin and gemcitabine.
Second-line treatment
There are currently three drugs which have been approved
in the U.S. and Europe for second-line treatment of
patients with advanced NSCLC after failure of first-line
chemotherapy: docetaxel, pemetrexed and erlotinib.
These drugs have proven to be effective in phase III trials
[18]. A phase III randomized trial including 571 patients
with advanced NSCLC previously treated with chemother-
apy showed that pemetrexed was comparable in terms of
clinical efficacy to docetaxel; in both arms, 1-year survival
rates were 29.7% [19]. Median progression-free survival
was also comparable in both arms (2.9 months), and
median survival time was 8.3 versus 7.9 months for peme-
trexed and docetaxel, respectively (non significant differ-
ence).
The BR.21 study was a phase III randomized double-blind
placebo-controlled trial assessing the efficacy of erlotinib
treatment of patients with advanced and chemotherapy-
refractory NSCLC [20]. A total of 731 patients were ran-
domly assigned in a 2:1 ratio to receive erlotinib or pla-
cebo. Patients were required to have received one or more
previous lines of chemotherapy; in addition, they could
have a PS score of 0–3. At the time of the study, peme-
trexed was not available, and there was concern about the
toxicity and effectiveness of further chemotherapy after
failure of standard chemotherapy in some patients, there-
fore it was reasonable to compare erlotinib with placebo
[21,22]. The primary endpoint of the study was overall
survival; secondary endpoints were response rates, stable
disease rate, duration of response, time to disease progres-
sion and quality of life. Forty-nine percent of patients had
received two previous chemotherapy regimens, and 93%
had been treated with platinum-based regimens.
Response rate was 8.9% in the erlonitib group, and less
than 1% in the placebo group; median response duration
was 7.9 months and 3.7 months, respectively. Median sur-
vival was 6.7 months with erlotinib and 4.7 months with
placebo (p < 0.001). One-year survival was 31% with erlo-
tinib and 21% with placebo. Although the 10% observed
difference in 1-year survival appears to be small, it should
be taken into account that initial studies on platinum
compounds in the first-line treatment setting also showed
a 10% difference in 1-year survival as compared with sup-
portive treatment. Results presented in ASCO 2007
(Annual Meeting of the American Society of Clinical
Oncology), obtained from the TRUST (TaRceva lUng can-
cer Survival Treatment) trial, which includes patients
cared for in real clinical practice, are very similar to those
reported in the BR.21 trial, and survival curves follow the
same pattern [23]. This underscores the fact that in every-
day practice erlotinib offers the same advantages as those
observed in clinical trials.
Quality of life
When treating patients with cancer, physicians seek the
best therapeutic results. However, patients do not always
have exactly the same priorities when setting therapeutic
goals. Generally, patients wish to experience symptom
improvement, few toxic effects and better quality of life.
They also expect to live longer.
A study conducted by Silvestri et al., which enrolled 81
patients with advanced NSCLC already treated with chem-
otherapy, showed that many patients would choose
chemotherapy treatment for its effects on quality of life
rather than for the potential survival offered by the treat-
ment [24]. Only 25% would choose chemotherapy if ben-
efits were exclusively related to survival. More recently, it
was noted that nearly 75% of patients would choose the
therapeutic regimen according to related adverse effectsBMC Proceedings 2008, 2(Suppl 2):S3 http://www.biomedcentral.com/1753-6561/2/S2/S3
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[25]. Surprisingly, the adverse effect most taken into
account when making the decision was chemotherapy-
related nausea. Similar results were observed in other
regions of the world such as Japan [26].
As previously mentioned, the BR.21 trial evaluated the
effect of erlotinib treatment on quality of life [20,27]. The
European Organization for Research and Treatment of
Cancer (EORTC) validated questionnaires were used, and
significantly greater improvements in overall quality of
life and in both physical and emotional functioning were
observed in the erlotinib arm as compared with the pla-
cebo arm. In addition, a significantly longer median time
to deterioration for cough, dyspnea and pain was
recorded. These data show that erlotinib not only pro-
longs survival in these patients but also improves their
symptoms and quality of life.
When effects of the other therapeutic options available for
second-line treatment are evaluated, treatment with
docetaxel is found to have shown some improvement in
pain and fatigue, but not in overall quality of life [28]. In
addition, these effects were achieved among patients
receiving the highest dose of docetaxel, which later had to
be discontinued due to dose-related severe adverse effects,
including mortality.
In the study comparing pemetrexed and docetaxel, no sig-
nificant differences among both drugs were found in over-
all burden of symptoms or in quality of life, despite the
more favorable profile of adverse effects of pemetrexed
[19].
Adverse effects
Erlotinib is not significantly associated with hematologic
adverse effects [20], while 40% of patients treated with
docetaxel and 5.3% of those receiving pemetrexed experi-
ence severe neutropenia, with 12.7% and 2% having
febrile neutropenia, respectively [19]. These effects signif-
icantly affect not only potential survival but also quality of
life.
Most commonly reported erlotinib-related adverse effects
were rash and diarrhea [20]. Diarrhea is not a major prob-
lem, since it may be managed with standard therapies.
Rash was found in around 1 out of 20 patients receiving
erlotinib. When rash develops on the face, it may cause
complications, but it is usually transient and does not pre-
vent continuation of treatment. In some cases it may be
necessary to reduce the dose of the drug, but ideally it
should not be discontinued. Moreover, there are data sug-
gesting that patients experiencing rash tend to have longer
survival [29].
Another aspect that should be considered is the need of
premedication and invasive procedures for the adminis-
tration of the various available therapies [30]. Both
docetaxel and pemetrexed require administration of pre-
medication or other related drugs, and are administered
intravenously; whereas erlotinib is administered orally,
and does not require concomitant administration of other
drugs, thus causing patients less inconvenience.
Relationship between objective response and benefits
In the analysis of data from the BR.21 trial related to
patients not showing objective response, i.e., those show-
ing stable disease or disease progression, it is found that
even without evidence of objective response, there is an
improvement in survival (median survival 8.25 months,
as compared to 6.8 months with placebo; hazard ratio
(HR) 0.82; CI 0.68–0.99; p = 0.037).
Apparently, erlotinib reduces the pace of disease progres-
sion, and this is associated with longer survival.
Efficacy according to patients' specific characteristics
When comparing different subgroups of patients treated
with the different therapeutic options now available, we
see that in the BR.21 trial, despite having enrolled more
patients with a PS score of 2 and patients with two or
more previous chemotherapy cycles, erlotinib has similar
effects on survival to those reported with docetaxel and
pemetrexed. Patients with ECOG score 0–1 and one prior
regimen show a survival of 9.42, 9.15 and 9.45 months
with erlotinib, docetaxel and pemetrexed, respectively
[19,20,30].
Moreover, the beneficial effect of erlotinib is observed in
all subgroups of patients examined separately, such as
women or men, smokers or non-smokers, and with differ-
ent histopathological features, as shown by the analysis
using Forest plots. However, there is less benefit among
smokers, and this could be related to the fact that these
patients have lower peak plasma concentration of the
drug than non-smokers. In addition, it should be noted
that rash is also correlated with maximum peak blood lev-
els of erlotinib.
Other characteristics, such as previous chemotherapy and
therapeutic response, time from diagnosis, EGFR status,
and ethnicity, do not cause survival benefit to erlotinib.
There is some tendency to consider that erlotinib is only
effective in certain subgroups of patients, such as women
or Asians, or among patients with adenocarcinoma. Anal-
ysis of data from subgroups included in the BR.21 trial
show that overall survival is similar among women and
men (HR 0.8 for both populations) [20]. Likewise, sur-
vival is similar among patients with adenocarcinoma andBMC Proceedings 2008, 2(Suppl 2):S3 http://www.biomedcentral.com/1753-6561/2/S2/S3
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epidermoid carcinoma (HR 0.7 and 0.67, respectively).
When comparing Asian patients with other ethnicities,
results are similar (HR 0.6 and 0.8, respectively). It should
be noted that these data were obtained from a relatively
small number of patients.
A most important group is that of male smokers with epi-
dermoid carcinoma. In this population, HR in the erlo-
tinib group (n = 100) is 0.66, and median survival was 5.5
months, as compared to 3.4 months in the placebo group
(n = 57) [31].
Another significant aspect is that of EGFR mutations. It
has been argued that only patients with certain specific
mutations respond to erlotinib. However, survival of
patients with such mutations (exon 19 and exon 21) who
received placebo during the BR.21 trial is found to be 9.1
months, as compared to 3.5 months in the remaining
patients with wild-type EGFR assigned to the placebo
group. Thus, these mutations should be considered to be
a prognostic factor, although they can be associated with
better objective tumour response to the agent, survival is
increased in both mutation and wild type patients [32].
As regards rash, in the TRUST trial 11% of patients
required a dose reduction due to this adverse effect [23].
This figure is not markedly different from that observed in
the BR.21 trial (6%). There are no significant differences
either between both trials as to the proportion of patients
developing any kind of rash.
Future options
Combination of erlotinib and bevacizumab in the sec-
ond-line treatment of patients with advanced NSCLC has
been evaluated, since the former, apart from its effect on
EGFR, has antiangiogenic properties. The evaluation of
this combination yields promising results [33]. In another
phase II trial including patients previously treated with
chemotherapy who were assigned to erlotinib plus beva-
cizumab, bevacizumab plus chemotherapy, or chemo-
therapy alone, a 1-year survival rate of 57.4% was
observed with the first combination [34].
Phase III studies are required to further assess these prom-
ising data.
Conclusion
Erlotinib is an adequate therapeutic option for the sec-
ond-line treatment of patients with advanced NSCLC.
This drug has shown to have similar efficacy to chemo-
therapy, with better tolerability and proven positive
effects in terms of survival, quality of life and symptom
improvement.
Since there are no significant differences in survival
among the subgroups, selection of patients who should
receive erlotinib is not justified.
Erlotinib administration should continue to be evaluated
as a first-line treatment in elderly patients with advanced
NSCLC, in those who do not derive a benefit from stand-
ard chemotherapy due to comorbid conditions, or in
those patients refusing conventional chemotherapy.
Erlotinib administration as first-line maintenance therapy
is being evaluated.
Combination of erlotinib and other agents, such as beva-
cizumab, has provided promising results that should be
confirmed in future studies.
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